9,672 results found

As we previously reported, this August the European Commission granted approval for Celltrion's STELARA biosimilar, STEQEYMA.

As discussed in the initial 2023 Healthcare Private Equity Outlook & Trends publication released in January 2023, sponsors and company management faced a number of notable headwinds as they entered 2023...

Since the enactment of the ACA, the pace of hospital and health system consolidation has accelerated to a level not seen since the late 1990s.

Watch the on-demand recording of the latest panel discussion from Ankura that showcases how consolidation trends among hospital providers may align with or differ from historical consolidation...

Eli Lilly announces a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, gaining access to an innovative antibody-engineering platform that selectively targets pathogenic autoantibodies in autoimmune and allergic diseases. The acquisition includes Merida's lead program MER511, currently in Phase 1 development for Graves' disease and thyroid eye disease, along with earlier-stage programs addressing food allergy, asthma, and kidney disease.

Partners from McDermott Will & Emery explore how European companies and investors can capitalize on China's rapidly growing biotech sector through innovative deal structures and strategic partnerships. The discussion examines emerging models like NewCo formations, equity investments, and co-development arrangements that enable European partners to access Chinese biotech innovation while leveraging Europe's clinical capabilities and regulatory expertise.

Below is a link to view the latest entry from the monthly Law360 that we publish relating to healthcare private equity investments.

Partner Sarah Hogan has contributed to American Health Law Association's second edition of Health Care Contracts: A Clause-by-Clause Guide to Drafting and Negotiation...

Johnson & Johnson has announced it has accepted a $4 billion binding offer from PE firm Carlyle Group for its Ortho Clinical Diagnostics business.

Surge Private Equity has announced it has invested in Elite Clinical Network (ECN) in a transaction valued at around $200 million.

Watch highlights from McDermott's HPE Miami 2023 event, which took place March 8-9 on the beach in sunny Miami, FL.

These are tough times in the biotech and pharmaceutical industries: Funding is drying up, investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping, activists are lurking and the headlines are anything but kind.

In a recent GEN Edge article, Duane Morris partner Rebecca Guzman discussed the state of M&A activity in the life sciences.

In this episode, hosts Payal Nanavati and Savanna Williams talk to Paul Pollock and Wayne Pryor about how private equity (PE) got its start in the health care industry, current trends in PE regulation, and where listeners can expect to see PE to continue investing in the industry.

Bart Walker, LauraLee Lawley and John Saran penned an article for DrBicuspid.com addressing increased governmental scrutiny of dental service organizations.

In part two of this two-part series, Matt Miller and Andrew Lloyd analyze representations and warranties insurance (RWI) in the health care M&A landscape.

Navigating the expanding defense technology subsector of the emerging company ecosystem requires careful planning and execution.